Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.

Earl Hubbell¹, Alpa V Patel², Christina A Clarke¹, Emily L Deubler², Eric T Fung¹, Rong Jiang¹, Allison W Kurian³, Cari Lichtman², Lauren R Teras², Oliver Venn¹, Nan Zhang¹, Charles Swanton⁴

¹GRAIL, Inc., Menlo Park, California, USA.

²Department of Population Science, American Cancer Society, Atlanta, Georgia, USA.

³Division of Oncology, Department of Medicine, and Department of Epidemiology & Population Health, Stanford School of Medicine, Stanford, California, USA.

⁴Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: Previous studies have estimated the mean sojourn and dwell times within stages for commonly screened cancer types. However, little is known about the preclinical detection window of circulating tumor DNA (ctDNA) (ie, ctDNA positivity), which is important for understanding multicancer early detection. METHODS: The duration of preclinical detectability and prognostic value of ctDNA de…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.